RxDoctor Payments Data

Cara Stansifer, NP

Nurse Practitioner · Fort Wayne, INNPI 1518273887

Payments from drug & device makers

$1,185in general payments, 2019–2025

Across 15 payments — averaging $78.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$364
  • Neurocrine Biosciences, Inc.$358
  • Paratek Pharmaceuticals, Inc.$125
  • Otsuka America Pharmaceutical, Inc.$116
  • Acadia Pharmaceuticals Inc$114
  • Sunovion Pharmaceuticals Inc.$69
  • plus $39 from 2 others

What the payments were for

  • Food & beverage$1,185100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,185 in reported general payments places this provider in the 75th percentile of 2,724 nurse practitioner providers in Indiana.

See all nurse practitioner providers in Indiana

Medicare billing

Part B allowed, 2024
$73,588
Medicare patients
197
Services billed
921

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate49$161,478
EliquisApixaban273$157,306
OzempicSemaglutide65$65,741
JardianceEmpagliflozin100$62,604
TrulicityDulaglutide54$55,290
XareltoRivaroxaban69$34,011
Trelegy ElliptaFluticasone/Umeclidin/Vilanter45$30,443
JanuviaSitagliptin Phosphate48$28,228
RexultiBrexpiprazole15$23,336
MyrbetriqMirabegron44$20,141
TradjentaLinagliptin52$20,112
Breo ElliptaFluticasone/Vilanterol36$15,228
GemtesaVibegron28$14,028
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog45$13,397
Potassium Chloride246$13,302

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$116$23,33615 claims
Sumitomo Pharma America, Inc.Gemtesa$21$14,02828 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,724 nurse practitioner providers in Indiana.

Other nurse practitioner in Fort Wayne

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →